Study of CFT8919 for advanced NSCLC with EGFR L858R mutation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, CFT8919, for people with a specific type of advanced lung cancer (non-small cell lung cancer with an EGFR L858R mutation) that has stopped responding to other treatments. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer with an EGFR L858R mutation.
- Your cancer has gotten worse after, or you can't take, standard treatments.
- You are 18 years or older and in generally good health (able to care for yourself).
- You have at least one tumor that can be measured on a scan.
- Your major organs (like bone marrow, liver, kidneys) are working well enough.
- You have not had certain other cancers or serious heart, lung, or bleeding problems recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
This trial tests two experimental drugs, JS212 and JS111, as a first treatment for advanced lung cancer with a specific EGFR mutation. It aims to see if the combination can shrink tumors and help people live longer.
Hear when a new Non-Small Cell Lung Cancer With EGFR Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.